uniQure NV (QURE) Trading Down 4.3%
Shares of uniQure NV (NASDAQ:QURE) traded down 4.3% on Tuesday . The stock traded as low as $8.84 and last traded at $8.89, with a volume of 283,070 shares. The stock had previously closed at $9.29.
QURE has been the topic of a number of recent research reports. Leerink Swann reaffirmed a “buy” rating on shares of uniQure NV in a report on Sunday, June 12th. HC Wainwright initiated coverage on shares of uniQure NV in a report on Thursday, August 4th. They issued a “buy” rating and a $21.00 target price on the stock. Cowen and Company reaffirmed a “buy” rating on shares of uniQure NV in a report on Thursday, June 2nd. Chardan Capital set a $35.00 target price on shares of uniQure NV and gave the company a “buy” rating in a report on Thursday, July 28th. Finally, Jefferies Group set a $28.00 target price on shares of uniQure NV and gave the company a “buy” rating in a report on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $29.10.
The company’s market cap is $218.90 million. The firm has a 50-day moving average price of $7.74 and a 200-day moving average price of $11.60.
uniQure NV (NASDAQ:QURE) last announced its earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. Equities analysts predict that uniQure NV will post ($3.45) earnings per share for the current year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.